Asset Details
Do you wish to reserve the book?
Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis
Do you wish to request the book?
Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis
2015
Overview
Background: In hemodialysis (HD) patients, zinc depletion caused by inadequate intake, malabsorption, and removal by HD treatment leads to erythropoiesis-stimulating agent (ESA) hyporesponsiveness. This study investigated the effects of zinc supplementation in HD patients with zinc deficiency on changes in the erythropoietin responsiveness index (ERI). Methods: Patients on HD with low serum zinc levels (<65 μg/dL) were randomly assigned to two groups: The polaprezinc group (who received daily polaprezinc, containing 34 mg/day of zinc) (n = 35) and the control group (no supplementation) (n = 35) for 12 months. All the 70 patients had been taking epoetin alpha as treatment for renal anemia. ERI was measured with the following equation: Weekly ESA dose (units)/dry weight (kg)/hemoglobin (g/dL). Results: There were no significant changes in hemoglobin levels within groups or between the control and polaprezinc groups during the study period. Although reticulocyte counts were increased immediately after zinc supplementation, this change was transient. Serum zinc levels were significantly increased and serum copper levels were significantly decreased in the polaprezinc group after three months; this persisted throughout the study period. Although there was no significant change in the serum iron or transferrin saturation levels in the polaprezinc group during the study period, serum ferritin levels significantly decreased following polaprezinc treatment. Further, in the polaprezinc group, ESA dosage and ERI were significantly decreased at 10 months and nine months, respectively, as compared with the baseline value. Multiple stepwise regression analysis revealed that the change in the serum zinc level was an independent predictor of lowered ERI. Conclusions: Zinc supplementation reduces ERI in patients undergoing HD and may be a novel therapeutic strategy for patients with renal anemia and low serum zinc levels.
Publisher
MDPI AG,MDPI
Subject
/ Aged
/ Anemia
/ Anemia - prevention & control
/ Blood
/ Carnosine - analogs & derivatives
/ copper
/ Dose-Response Relationship, Drug
/ Epoetin Alfa - therapeutic use
/ Erythropoietin - pharmacology
/ Erythropoietin - therapeutic use
/ Female
/ ferritin
/ Humans
/ Iron
/ Kidney Failure, Chronic - blood
/ Kidney Failure, Chronic - therapy
/ Male
/ Organometallic Compounds - pharmacology
/ Organometallic Compounds - therapeutic use
/ patients
/ Proteins
/ Renal Dialysis - adverse effects
/ Trace Elements - pharmacology
/ Trace Elements - therapeutic use
/ zinc
